

Item 2.01 Completion of Acquisition or Disposition of Assets.

On May 23, 2018, Spark Therapeutics, Inc. (the “Company”) closed its previously announced transaction with Jazz Pharmaceuticals Ireland Limited (“Jazz”) pursuant to which the Company sold its Rare Pediatric Disease Priority Review Voucher (“PRV”) to Jazz in accordance with the terms of the Asset Purchase Agreement (the “Agreement”) entered into by the parties on April 30, 2018. The PRV was awarded to the Company by the U.S. Food and Drug Administration in connection with the approval of LUXTURNA™ (voretigene neparvovec-rzyl), a one-time gene therapy product indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. In consideration for the PRV, Jazz paid the Company \$110,000,000 upon closing of the PRV purchase.

The foregoing description of the Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Agreement. The Company intends to file a copy of the Agreement with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SPARK THERAPEUTICS,
INC.

Date: May 23, 2018 By: /s/ Joseph W. La Barge
Joseph W. La Barge
Chief Legal Officer